An FDA panel of experts is scheduled to discuss the confirmatory study of Alzheimer's drug Leqembi on June 9, 2023.Leqembi, co-developed by Eisai and Biogen, was approved for the treatment of Alzheimer's disease, under the Accelerated Approval Pathway, on Jan.6, 2023.The confirmatory study is intended to support the conversion of the accelerated approval of Leqembi to a traditional approval. The FDA’s decision in determining whether to convert accelerated approval of Leqembi to a traditional approval is due on July 6, 2023.BIIB closed Friday’s (May 26, 2023) trading at $298.66, up 0.51%.